BioNTech SE
https://biontech.de/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioNTech SE
Coronavirus Update: As Pfizer/BioNTech Begin Omicron Vaccine Tests, Regulators Want To Explore Multivalent Route
Pfizer explores options for new vaccine update, Veklury expands to non-hospitalized patients but Regeneron and Lilly therapies stopped in face of Omicron efficacy drop-off.
Clive Dix: Industry Veteran, Vaccines Expert And Biotech Advocate
With more than 30 years’ experience in pharma and biotech, Clive Dix has seen the industry evolve and take on many challenges. He spoke to Scrip about his career journey, the future of biotech and his expectations for 2022 – another year under the cloud of COVID-19.
Coronavirus Update: Generics And Hurdles For Molnupiravir, More Japan Approvals
More generic deals but also US approval hurdles for Merck's oral antiviral, while Japan approves more options and Valneva's vaccine candidate shows promise against Omicron.
Pfizer’s COVID-19 Vaccine Data In Young Children Could Place US FDA In Awkward Position Again
The agency is considering how to move forward as Pfizer studies a third shot after missing an efficacy endpoint in children age 2 to 5.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Other Names / Subsidiaries
-
- BioNTech US Inc.
- Biopharmaceutical New Technologies AG
- Neon Therapeutics, Inc.
- BioNTech AG